Navigation Links
Primera Biosystems Raises $21 Million in Series B Private Round

MANSFIELD, Massachusetts, January 8 /PRNewswire/ -- Primera Biosystems, Inc., an emerging molecular diagnostics company with assay programs in infectious disease and oncology, announced today that it has closed on $21 million of Series B financing led by Abingworth and joined by Interwest Partners. Existing investors Malaysian Technology Development Corporation (MTDC), MPM Capital, Burrill & Company and the Invus Group also participated in the round.

"Primera plans to use this financing to complete development of our instrument system, reagent kits for disease-specific clinical research, future diagnostic tests as well as support ongoing research and development efforts," said Martin L. Verhoef, President and Chief Executive Officer of Primera Biosystems, Inc. "With help from our new and existing investors, we will stay ahead of the field by developing molecular diagnostics that have significant impact on patient management and deliver real benefits for doctors, patients and payers."

Primera is developing a proprietary nucleic acid analysis system, "STAR" (Scalable Target Amplification Routine), that combines in a single bench-top system the best features of quantitative real-time PCR with - true multiplexing of 60 or more targets. By increasing throughput and lowering costs -- while maintaining accuracy and quantification -- the STAR system has the potential to become the premier next generation real-time PCR platform for use in clinical development and diagnostics. The technology was invented by Vladimir Slepnev Ph.D., Primera's Chief Scientific Officer and co-founder. The technology can be applied for gene expression, DNA/RNA analysis, micro RNA analysis, mutation analysis and methylated DNA analysis. The Company's first test leveraging STAR is ViraQuant(TM), a market-ready assay for the simultaneous quantitative measurement of multiple viral agents that cause infections in immune compromised patients. A multiplex fungal test will follow. These assays will permit rapid, efficient and quantitative measurement of pathogens and will help choose the appropriate therapeutic intervention, taking treatment from empirical therapy to complete and personalized medicine. Primera plans to commercialize its STAR platform and assay reagents to hospital and reference laboratories that service the relevant clinical populations, and will seek future regulatory approval.

"Multiplex molecular assays are becoming extremely important for the practice of medicine," said Vincent J. Miles, Ph.D, Venture Partner with Abingworth. "We believe that Primera's ingenious technology represents the most viable solution for highly multiplexed quantitative real-time PCR, the gold standard for accurate results in molecular diagnostic tests, and will have a major impact on testing procedures in the company's target markets."

Primera's new Board of Directors will be led by Laurence McCarthy as Executive Chairman and will include Martin Verhoef, President and CEO; Michael Bigham and Vincent Miles, Abingworth; Nina Kjellson, Interwest; Azlin Alias, Malaysian Technology Development Corporation and Kazumi Shiosaki (co-founder), MPM Capital.

About Abingworth

Abingworth is an investment firm dedicated to the life sciences sector on both sides of the Atlantic. The company invests across all stages of development, including early-stage as well as public companies. Abingworth has provided backing for more than 100 unquoted life science businesses. Over 70% of these have gone public or have merged or been acquired. Abingworth has funds under management of more than $1.25 billion. Founded in 1973, Abingworth has offices in London, Cambridge (UK), Menlo Park (California) and Boston. More information can be found at

About InterWest Partners

Investing since 1979, InterWest Partners is a leading diversified venture capital firm currently investing InterWest IX, a $600 million fund. With more than $2B in capital under management, InterWest takes a long-term collaborative approach to venture funding, providing early-stage and ongoing capital, management development and access to a broad network of resources. More information can be found at

About MTDC

Technology Development Corporation (MTDC) is the leading integrated venture capital (VC) solutions provider in Malaysia. It is an agency under the Ministry of Science, Technology and Innovation (MOSTI) and its majority shareholder is Khazanah Nasional Berhad, the Malaysian government investment arm. MTDC was incorporated on March 1992 with the focus on commercializing research results of universities/research institutions, identifying and transferring emerging and strategic technologies for adoption by industries, and encouraging the growth of technology-based enterprises in Malaysia. As an integrated VC company, MTDC provides services to individuals, entrepreneurs and companies in the areas of technology financing/funding, technology grants, technology incubators and value-added consultancy. These services form the core of MTDC's activities to create, nurture and promote Malaysian technology companies in strategic thrust areas. More information can be found at

SOURCE Primera Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
2. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
3. Pearl Therapeutics Raises $15.5 Million in Private Financing
4. Enobia Pharma Raises $40.1 Million Series B Financing
5. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
6. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
7. VisEn Medical Raises $7 Million in Series B Financing
8. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
9. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
10. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
11. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... --> --> ... Synthesis Market by Product & Services (Primer, Probe, Custom ... RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - ... is expected to reach USD 1,918.6 Million by 2020 ... of 10.1% during the forecast period. Browse ...
Breaking Biology Technology:
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
(Date:11/9/2015)... Nov. 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced broader entry into the automotive market with a ... the pace of consumer electronics human interface innovation. Synaptics, ... ideal for the automotive industry and will be implemented ... Europe , Japan , ...
Breaking Biology News(10 mins):